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A Convergent Strategy to Febrifugine and Related Compounds  
T. M. M. Maiden,
a
 N. Mbelesi,
 a
 P. A. Procopiou,
b
 S. Swanson,
b
 and J. P. A. Harrity
 *a
 
We report a modular five step synthetic route to the febrifugines 
that employs 2-(chloromethyl)allyl-trimethylsilane as a conjuctive 
reagent for the coupling of the piperidine and quinazolinone 
groups. We also demonstrate the application of a recent Rh-
catalyzed quinazolinone synthesis for the facile generation of 
febrifugine analogs.  
Introduction 
Quinazolinones are an important class of heterocycles in 
organic chemistry, and they are found in many natural 
products and biologically active compounds.
1
 Most methods of 
generating these compounds rely on the availability of 
anthranilic acids and related systems.
2
 Recently however, we 
have reported a directed amidation strategy for the synthesis 
of quinazolinones, which allows a broad range of these 
compounds to become available from simple (and often 
commercial) carboxylic acids.
3
  
Amongst the many important quinazolinone-containing 
compounds found in nature and medicinal chemistry, the 
febrifugine family of alkaloids together with their synthetic 
analog halofuginone, have attracted considerable interest 
(Figure 1).
4
 Febrifugine, isolated from the roots of Dichroa 
febrifuga plant and Hydrangea, has powerful antimalarial 
properties against Plasmodium falciparum, however, because 
of side-effects, such as severe vomiting and hepatotoxicity, is 
not used clinically. The synthetic analog halofuginone lactate is 
used as an antiparasitic agent in veterinary medicine for the 
treatment of neonatal dairy calves preventing infection with 
cryptosporidium and in poultry against coccidiosis.
5
 
Furthermore, halofuginone inhibits the development of human 
Th17 cells and collagen type 1 gene expression and has the 
potential to be used for the treatment of scleroderma, cancer, 
restinosis, autoimmune disorders and fibrotic diseases.
6
 
Halofuginone hydrobromide (tempostatin
TM
) has been tested 
in Phase 1 clinical studies to assess dose-limiting toxicities, the 
maximum tolerated dose and human pharmacokinetics.
7
 
Observed side-effects included nausea, vomiting and fatigue, 
and the recommended maximum dose for further studies was 
determined to be 0.5 mg/day.  Other analogues of febrfugine 
and halofuginone, devoid of toxicity and side-effects are 
therefore required for further exploitation and development 
of new medicines.
  
 
Figure 1. Febrifugine and related analogs. 
 
Despite the attractive biological applications which the 
febrifugine family offer, only limited SAR has been 
investigated.
8
 We sought to develop a modular route to the 
febrifugine family and synthesize biologically relevant analogs 
by utilizing our C-H amidation cyclocondensation sequence.  
With respect to febrifugine, Ogasawara prepared this 
compound through the synthesis of a 2-allyl piperidin-3-ol
 
derivative that allows the final compound to be delivered after 
alkene epoxidation, quinazolinone addition, oxidation level 
adjustment and protecting group manipulation.
9
 This route has 
the advantage of introducing the quinazolinone at a late-stage 
thereby providing a means for acquiring SAR at this position. 
On the other hand, several steps are required before the key 
piperidine intermediate is made available.  
In an effort to devise a convergent route to this class of 
compounds and explore SAR, we were attracted to the 
approaches of Burgess and Rutjes. Burgess had employed a 
tetrahydropyridine oxide that allowed the quinazolinone 
containing ketone fragment to be introduced in one step.
10
 
Rutjes however had devised an elegant allylsilane conjunctive 
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reagent 2 that offered a highly convergent approach to a late-
stage lactam analog of febrifugine.
11
 We envisaged that 
combining these strategies could offer a rapid and convergent 
method for the synthesis of febrifugine and its analogs that 
included the option of exploiting our C-H amidation 
methodology for the late-stage introduction of a range of 
bespoke quinazolinones. Our strategy is summarized in 
Scheme 1. 
Results and Discussion 
Our first task was to develop a scalable method for the 
ĐŽƵƉůŝŶŐŽĨZƵƚũĞƐ ?ĐŽŶũƵŶĐtive reagent 2 to the piperidine ring 
of the target compound series. We therefore investigated the 
synthesis of functionalized piperidines 1a-c, all of which 
represented potential precursors to the first key intermediate  
 
 
 
Scheme 1. Convergent route to febrifugine analogs. 
 
3 (Scheme 2). Accordingly, commercial Cbz-protected 
tetrahydropyridine was subjected to dihydroxylation followed 
by functionalization of the diol moiety as a carbonate and 
diester
12
 1a,b in synthetically useful overall yields. In addition, 
we prepared epoxide 1c. Our preliminary method for 
epoxidation employed freshly prepared DMDO (method A) but 
the in situ generation of this reagent (method B) proved to be 
more practical and allowed gram quantities of substrate to be 
accessed more conveniently.  
 
 
 
Scheme 2. Synthesis of functionalized piperidines.  
 
Aminals 1a-c provided a platform to explore the efficiency and 
stereoselectivity of the allylation reaction using conjunctive 
reagent 2, and our results are summarized in Table 1. 
Carbonate 1a provided piperidine 3a in modest yield and with 
a marginal preference for the trans-diastereomer. Diester 1b 
and epoxide 1c performed similarly and provided compounds 
3a,b with low cis/trans-selectivity. As low selectivities were 
observed in every case, we decided to use the route that 
employed 1c as this encompassed only a two-step sequence. 
Moreover, as cis/trans-3a were separable by chromatography 
this procedure allowed gram quantities of each intermediate 
to be prepared for subsequent transformation to the target 
compounds. 
 
Table 1 Coupling reaction of allylsilane 2 with piperidines 1a-d 
 
 
Entry
a
 Piperidine
 
R Yield (trans:cis)
b
 
1 1a H; 3a 40% (1.2:1) 
2
c 
1b Ac; 3b 63% (1:1.3) 
3 1c H; 3a 66% (1:1.1) 
a
Reaction conditions: 1a-d, 2 (1.2 equiv), BF3.OEt2 (2 equiv) in CH2Cl2 stirred 
at -78 
o
C under N2 for 1 h and warmed to rt overnight. 
b
Isolated yields of 
purified compounds. 
c
1 Equiv BF3.OEt2 used in this case. 
We next turned our attention to the introduction of the 
quinazolinones, with a view to using our recently developed 
Rh-catalyzed ortho-amidation cyclocondensation 
sequence.
3(a),(b)
 Employing this methodology, we were able to 
readily prepare a range of functionalized quinazolinones. 
Halofuginone quinazolinone 4a, its corresponding isomer 4b, 
aza-quinazolinone 4c and the quinazolinone of the tyrosine 
kinase inhibitor, 4d. The required quinazolinones for the 
febrifugine analog 4f and the mono-Br 4e were acquired from 
a commercial source (Scheme 3). 
With quinazolinones 4a-f in hand, we next explored the 
coupling of these heterocycles with the trans-piperidine 3a. In 
the event, the couplings took place smoothly in all cases to 
deliver a family of fully coupled febrifugine analogs (Scheme 
4). Having successfully coupled the key fragments, our final 
objective was to confirm that intermediates 5a-f could be 
taken forward to the corresponding febrifugine derivatives.  
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Scheme 3. Synthesis of quinazolinones by directed CH-
amidation. 
 
 
Scheme 4. Synthesis of febrifugine and analogs. 
 
We employed an oxidative cleavage and deprotection 
protocol, using a modification of the method described by 
Rutjes.
11
 We were pleased to find that halofuginone trans-5a, 
febrifugine trans-5f and analogs trans-5b-e were all isolated in 
good yield under these conditions as the HBr salts. Moreover, 
isolation of the free base of trans-5f followed by 
recrystallization from CH2Cl2/petroleum ether allowed us to 
record the first reported X-ray crystal structure of febrifugine, 
thereby unambiguously confirming the trans-stereochemistry 
of the piperidine ring.
13 
 
 
 
Scheme 5. Investigation towards the synthesis of the iso-
febrifugines. 
 
We next turned our attention to the synthesis of the 
corresponding cis-analogs of the febrifugines, but found these 
transformations to be less straightforward (Scheme 5). 
Specifically, while cis-6 (iso-halofuginone) could be prepared 
and isolated as the free base, albeit in low yield, the 
corresponding derivatives derived from other quinazolinones 
could not be isolated cleanly by this process. Indeed, evidence 
for the instability of these products under acid was uncovered 
during the attempted syntheses of cis-6. Specifically, we were 
able to isolate imine 7 as major by-products in this case, and 
the compound structure was assigned by NMR spectroscopy 
and mass spectrometry, and by comparison to literature data 
of a similar compound.
14
 We believe that this side reaction is 
ŝŶŝƚŝĂƚĞĚ ďǇ ĂŶ ĂĐŝĚ ĐĂƚĂůǇǌĞĚ ɴ-amino elimination, as this 
pathway has been invoked as a mechanism for cis/trans 
isomerization in the febrifugines. Furthermore, and as shown 
in Scheme 5, enolization of the ring-opened product can 
provide a 1,4-diketone that undergoes condensation to the 
observed imine 7. 
As we had developed a convergent strategy for the 
preparation of biologically relevant trans-febrifugine analogs, 
especially those that contained halogenated quinazolinone 
fragments, we wanted to demonstrate that this chemistry 
could offer the opportunity for directed analog synthesis. 
Specifically, we were intrigued by a recent report by Zhou who 
employed crystallography to show how halofuginone binds 
and inhibits ATP-dependent, human prolyl tRNA synthetase 
(ProRS).
15
 We were especially drawn to the presence of the 
glutamic acid 1100 residue which was in close proximity to the 
bound quinazolinone, and were interested in the introduction 
of a basic moiety such as an aminomethyl group to increase 
the binding affinity of these compounds. We envisaged that 
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quinazolinone 4a would offer convenient access to these 
compounds. 
Accordingly, we designed a route to a selection of amino-
methyl functionalized febrifugine analogs. Our strategy for 
introduction of the aminomethyl motif was underpinned by 
cross-coupling of DŽůĂŶĚĞƌ ?Ɛ ƉŽƚĂƐƐŝƵŵ ĂŵŝŶŽ-methyl 
trifluoroborate salts.
16
 In the event, coupling aminomethyl-
borate salts to quinazolinone 4a proceeded in low yield, and 
we attributed this to low solubility of the coupling partners. 
Gratifyingly, we found that employing the quinazolinone 
precursors derived from our C-H amidation chemistry 
satisfactorily addressed this problem. Specifically, 
aminoquinazoline 8 offered improved conversion and isolated 
yields of cross-coupled products. Subsequent hydrolysis 
allowed access to a range of amino-methyl functionalized 
quinazolinones 9a-c (Scheme 6). 
With the required quinazolinones in hand, the aminomethyl 
functionalized analogs were smoothly progressed through to 
the final compounds trans-10a-c as HBr salts (Scheme 7). 
Biological evaluation of the amino-methyl and halogenated 
analogs is ongoing and will be reported in due course. 
Conclusions 
We have developed a modular route to the febrifugines that 
delivers these compounds in a 5 step sequence. This synthesis 
route offers significant scope for analog preparation, as 
demonstrated by the synthesis of amino-methyl derivatives, 
and in this regard, we highlight the potential of a recent 
catalytic quinazolinone synthesis for the diversification of 
these compounds. 
 
 
 
Scheme 6. Synthesis of amino-methyl functionalized 
quinazolinones. 
 
 
 
Scheme 7. Synthesis of amino-methyl febrifugine analogs. 
Experimental 
Compounds 1b,
10
 4a,
3(a)
 4c,
3(a)
 4d,
3(b)
 Et- and 
morpholineaminomethyl potassium trifluoroborates
16
 were 
synthesized according to literature procedures.  
 
Benzyl 2,3-dihydroxypiperidine-1-carboxylate.
10
 To a solution 
of N-Boc-3,4-dihydro-2H-pyridine (1.0 g, 5.4 mmol) in acetone 
(50 mL) and water (5 mL) were added a few crystals of osmium 
tetroxide. The reaction was stirred at room temperature and 
monitored by TLC analysis. After completion, the mixture was 
cooled and quenched with an aqueous saturated solution 
of sodium metabisulfite (10 mL). Water (10 mL) was added and 
the product was extracted with ethyl acetate (3 x 10 mL). 
The combined organic layers were washed with brine and 
dried over MgSO4. The mixture was filtered and concentrated 
under reduced pressure to give the crude product. The crude 
residue was purified via flash column chromatography eluting 
with petroleum ether : EtOAc (6 : 4) to give the title compound 
(922 mg, 68%); 
1
H NMR (400 MHz, CDCl3 ? ? ɷ  ? ? ? ?- 7.34 (5H, 
m), 5.75 (1H, d, J = 3.5 Hz), 5.13 (2H, s), 3.90 - 3.82 (1H, m), 
3.64 - 3.56 (1H, m), 3.10 (1H, dt, J = 12.0, 2.0 Hz), 1.86 - 1.78 
(1H, m), 1.74 - 1.66 (2H, m), 1.56 - 1.46 (1H, m); 
13
C NMR (101 
MHz, CDCl3 ? ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ?  ? ? ? ?, 
67.5, 36.1, 26.6, 23.5. 
 
Benzyl 2-oxotetrahydro-[1,3]dioxolo[4,5-b]pyridine-4(3aH)-
carboxylate (1a). To a solution of benzyl 2,3-
dihydroxypiperidine-1-carboxylate (200 mg, 0.79 mmol) and 
pyridine (251 mg, 3.18 mmol) in dichloromethane (6 mL) at 0 
°C was added triphosgene (259 mg, 0.87 mmol). The reaction 
was stirred at ice/water bath temperature for 6 h. After 
completion, diethyl ether (10 mL) was added and the crude 
mixture was washed with saturated aqueous CuSO4. The 
organic extract was washed with brine, dried over MgSO4 and 
the solvent removed under reduced pressure to afford 1a as a 
clear oil (141 mg, 64%);
 1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ 7.53 - 
7.19 (5H, m), 6.64 (1H, d, J = 8.0 Hz), 5.19 (2H, s), 5.11  ? 5.05 
(1H, m), 3.66  ? 3.55 (2H, m), 1.83  ? 1.71 (3H, m), 1.68  ? 1.57 
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(1H, m); 
13
C NMR (101 MHz, DMSO-d
6 ? ?ɷ 154.8, 153.7, 136.4, 
128.9, 128.6, 128.2, 128.0, 82.5, 73.3, 67.8, 23.9, 16.0; FTIR: 
ʆmax 2956 (w), 1794 (s), 1704 (s), 695 (s); HRMS calculated for 
C14H15NO5 (ES
+
)(+Na
+
): 300.0842. Found: 300.0846. 
 
Benzyl 7-oxa-2-azabicyclo[4.1.0] heptane-2-carboxylate (1c). 
Oxone monopersulfate (45.0 g, 147.0 mmol) was added 
portion wise to a solution of sodium bicarbonate (60.0 g, 720.0 
mmol) in water (300 mL), and the mixture was allowed to stir 
for 10 mins. To this solution was added acetone (240 mL) and 
benzyl 3,4-dihydropyridine-1(2H)-carboxylate (4.0 g, 18.0 
mmol). The mixture was allowed to stir for 16 h at room 
temperature. After completion, water (100 mL) was added and 
the organic layer extracted with ethyl acetate (2 x 50 mL). The 
combined organic layers were dried over MgSO4 and the 
solvent removed under reduced pressure to afford the crude 
product, which was purified by flash column chromatography 
eluting with cyclohexane : EtOAc (2 : 8) to afford 1c as a clear 
oil (3.5 g, 83%) and as a 1 : 1 mixture of rotamers. 
1
H NMR (400 
MHz, CDCl3 ? ?ɷ  ? ? ? ?  ? ?, ?Ɛ ? ? ? ? ? ?  ? ? ? ?, ?Ɛ ? ?  ? ? ? ?  ? ? ? ?, ?Ɛ ? ?   ? ?
(2H, s), 4.17 - 4.11 (0.5H, m), 3.95 - 3.85 (2H, m), 3.65 - 3.55 
(0.5H, m), 3.24 - 3.16 (1H, m), 3.12 - 3.04 (1H, m), 1.57 - 1.40 
(2H, m); 
13
C NMR (101 MHz, CDCl3 ? ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?
128.5, 128.2, 128.1, 128.0, 127.96, 127.90, 78.2, 69.0, 67.5, 
67.0, 60.3, 38.5, 26.7, 25.0, 23.5, 21.0, 18.4, 14.2 ? &d/Z ? ʆmax 
3375 (w), 2947 (w), 1673 (s), 1255 (s), 987 (s);
 
 HRMS 
calculated for C13H15NO3 (ES
+
)(+H
+
): 234.2613. Found: 
234.2614. 
 
Benzyl 2-(2-chloromethyl)allyl)-3-methylpiperidine-1-
carboxylate (trans- and cis-3a). To a solution of benzyl 7-oxa-
2-azabicyclo[4.1.0]heptane-2-carboxylate (3.5 g, 149.0 mmol) 
and chlorotrimethylsilane (2.9 g, 179.0 mmol) in 
dichloromethane (40 mL) at -78 °C, BF3.OEt2 (2.1 g, 149.0 
mmol) was added. The reaction was allowed to stir overnight. 
Aqueous NaHCO3 (20 mL) was added and the reaction mixture 
was extracted with EtOAc (2 x 20 mL). The combined organic 
layers were dried over MgSO4 and the solvent was removed 
under reduced pressure to afford the crude oil which was 
purified by chromatography eluting with petroleum ether : 
EtOAc (4 : 6) to afford trans-3a as a clear oil (1.5 g, 31%), and 
cis-3a as a clear oil (1.7 g, 35 %). trans-3a (1 : 1 mixture of 
rotamers): 
1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ ? ? ? ?- 7.30 (5H, m), 
5.16 - 5.14 (1H, m), 5.08 - 4.98 (2H, m), 4.80 - 4.78 (1H, m), 
4.35 - 3.95 (3H, m), 3.90 - 3.85 (1H, m), 3.65 - 3.55 (1H, m), 
2.97 - 2.82 (1H, m), 2.35 - 2.25 (2H, m), 1.80 - 1.70 (2H, m), 
1.60 - 1.55 (2H, m), 1.35 - 1.25 (1H, m);
 13
C NMR (101 MHz, 
DMSO-d
6 ? ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? 
128.2, 128.0, 127.6, 117.6, 117.3, 66.6, 66.3, 65.9, 65.4, 55.7, 
55.4, 53.2, 48.2, 47.9, 38.9, 38.6, 32.5, 26.0, 24.4, 24.1; FTIR: 
ʆmax 3444 (w), 2938 (w), 1670 (s), 1424 (s); HRMS calculated for 
C17H23NO3
35
Cl2 (ES
+
)(+H
+
): 324.1366. Found: 324.1374. cis-3a (1 
: 1 mixture of rotamers): 
1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ ?.40 - 
7.29 (5H, m), 5.12 - 4.99 (4H, m), 4.45 - 4.40 (2H, m), 4.30 - 
4.25 (1H, m), 4.20 - 4.15 (2H, m), 4.05 - 3.95 (1H, m), 3.85 - 
3.75 (1H, m), 3.65 - 3.55 (1H, m), 2.86 - 2.74 (2H, m), 1.66 - 
1.62 (2H, m), 1.42 - 1.30 (1H, m);
 13
C NMR (101 MHz, DMSO-
d
6
) ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?      ? ?
128.1, 127.7, 117.5, 117.1, 68.2, 67.8, 66.8, 66.4, 55.4, 54.4, 
 ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ? &d/Z ? ʆmax  
3444 (w), 2938 (w), 1670 (s), 1424 (s);
 
HRMS calculated for 
C17H23NO3
35
Cl2 (ES
+
)(+H
+
): 324.1366. Found: 324.1367. 
 
Synthesis of 4-chloro-3-bromo-N-(2-hydroxyethyl)benzamide. 
To a stirred solution of 4-chloro-3-bromo benzoic acid (5.0 g, 
21 mmol) in MeCN (35 mL) was added CDI (3.79 g, 23.4 mmol). 
The reaction mixture was allowed to stir for a period of 2 
hours at room temperature before ethanol (2.45 g, 53.1 mmol) 
was added via syringe. The reaction was then stirred overnight 
at room temperature, before diluting with dichloromethane 
and transferring to a separating funnel. The organic phase was 
then subsequently washed with a saturated solution of 
NaHCO3 (aq.) and deionised water. The organic layer was dried 
over anhydrous MgSO4, filtered and the solvent was removed 
in vacuo to afford the crude ester product. To a dried round 
bottomed flask was added the crude ester product (5.00 g, 
18.8 mmol) and heated to 55 °C with stirring. Upon reaching 
the desired temperature ethanolamine (1.72 g, 28.2 mmol) 
was added slowly via syringe and the reaction was stirred for 3 
h before cooling to room temperature, and stirring for a 
further 18 hours. The crude reaction mixture was then purified 
by flash column chromatography on silica gel eluting with 
dichloromethane and methanol (1% MeOH to 20% MeOH) to 
afford the amide product as a colourless solid (3.37 g, 64%). 
M.p.: 166  ? 167 °C; 1H NMR (400 MHz, DMSO-d6 ? ?ɷ ? ? ? ? ? ?, ?ƚ ?
J = 5.5 Hz), 8.23 (1H, d, J = 2.0 Hz), 7.86 (1H, dd, J = 8.5, 2.0 Hz), 
7.73 (1H, d, J = 8.5 Hz), 4.74 (1H, t, J = 5.5 Hz), 3.55  ? 3.47 (2H, 
m), 3.35  ? 3.29 (2H, m  ? peak overlapped with residual H2O); 
13
C NMR (100.6 MHz, DMSO-d
6 ? ?ɷ  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?  ? ? ? ? ? ?
130.5, 128.1, 121.5, 59.5, 42.3 FTIR: vmax
 
(neat) 3289 (m), 1641 
(m), 1550 (m), 1466 (m), 1328 (m), 1248 (m), 1057 (s), 1023 
(m), 751 (m); HRMS calculated for C9H10
81
Br
35
ClNO2 (ES
+
)(+H
+
): 
279.9516. Found: 279.9554.  
 
Synthesis of 2-(4-chloro-3-bromophenyl)-4,5-dihydrooxazole. 
To a dried round bottomed flask was added 4-chloro-3-bromo-
N-(2-hydroxyethyl)benzamide (3.00 g, 10.8 mmol) and dry 
dichloromethane (18 mL). With stirring NEt3 (2.07 g, 20.5 
mmol) was then added, followed by DMAP (263 mg, 2.15 
mmol) and p-TsCl (3.49 g, 18.3 mmol). The reaction mixture 
was allowed to stir at room temperature overnight, before 
being diluted with dichloromethane and water. The mixture 
was then transferred to a separating funnel and the layers 
partitioned. The aqueous layer was further extracted with 
dichloromethane. The combined organic layers were dried 
over anhydrous MgSO4, filtered and the solvent was removed 
in vacuo. The crude residue was dissolved in MeOH (22 mL) 
and NaOH pellets (1.29 g, 32.3 mmol) were added in one 
portion. The reaction mixture was stirred at room temperature 
for 2 h before removing the solvent in vacuo. The residue was 
dissolved in dichloromethane and water, and transferred to a 
separating funnel. The layers were partitioned and the 
aqueous layer was further extracted with dichloromethane 
and ethyl acetate. The combined organic layers were dried 
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over anhydrous MgSO4, filtered and the solvent was removed 
in vacuo. The residue was purified by flash column 
chromatography on silica gel eluting with petroleum ether 
(40/60) and ethyl acetate (0% ethyl acetate to 100% ethyl 
acetate) to afford the oxazoline product as a colourless solid 
(2.26 g, 81%). M.p.: 75  ? 76 °C; 1H NMR (400 MHz, CDCl3 ? ? ɷ
8.12 (1H, d, J = 2.0 Hz), 7.73 (1H, dd, J = 8.5, 2.0 Hz), 7.41 (1H, 
d, J = 8.5 Hz), 4.37 (2H, t, J = 9.5 Hz), 3.99 (2H, t, J = 9.5 Hz); 
13
C 
NMR (100.6 MHz, CDCl3 ? ?ɷ  ? ?2.9, 137.8, 133.6, 130.6, 128.3, 
128.1, 122.8, 68.3, 55.4; FTIR: vmax
 
(neat) 2973 (w), 1650 (m), 
1466 (m), 1372 (m), 1261 (m), 1238 (m), 1067 (s), 1016 (m); 
HRMS calculated for C9H8
81
Br
35
ClNO (ES
+
)(+H
+
): 261.9450. 
Found: 261.9451. 
 
Synthesis of N-(4-bromo-5-chloro-2-(4,5-dihydrooxazol-2-
yl)phenyl)-2,2,2-trifluoroacetamide. To a dried round 
bottomed flask equipped with a stirrer bar and reflux 
condenser was added 2-(4-chloro-3-bromophenyl)-4,5-
dihydrooxazole (3.50 g, 13.4 mmol), [RhCp*Cl2]2 (69 mg, 0.13 
mmol, 1 mol %), AgSbF6 (154 mg, 0.520 mmol, 4 mol %), 
PhI(OAc)2 (5.41 g, 16.8 mmol) and trifluoroacetamide (1.27 g, 
11.2 mmol). The system was evacuated and refilled with 
nitrogen (3 times), followed by the addition of dry 
dichloromethane via syringe (110 mL). The reaction mixture 
was stirred at reflux (40  ? 45 °C) for 24 h. After cooling to room 
temperature the solvent was removed in vacuo and the 
residue was purified by flash column chromatography on silica 
gel eluting with petroleum ether (40/60) followed by 
dichloromethane to afford the aminated product as a 
colourless solid (2.29 g, 46%). M.p.: 109  ? 110 °C; 1H NMR (400 
MHz, CDCl3 ? ?ɷ ?3.63 (1H, s), 8.86 (1H, s), 8.11 (1H, s), 4.46 (2H, 
t, J = 9.5 Hz), 4.18 (2H, t, J = 9.5 Hz); 
13
C NMR (100.6 MHz, 
CDCl3 ? ? ɷ  ? ? ? ? ?  ?Ƌ ?J = 38.5 Hz), 163.2, 139.0, 137.2, 133.9, 
121.9, 117.5, 115.8 (q, J = 288.5 Hz), 114.3, 67.1, 54.6; 
19
F NMR 
(376.5 MHz, CDCl3 ? ?ɷ  ? 76.0; FTIR: vmax/ cm-1 (neat) 2990 (w), 
1711 (m), 1607 (m), 1523 (m), 1261 (s), 1147 (s), 1073 (s); 
HRMS calculated for C11H8
81
Br
35
ClF3N2O2 (ES
+
)(+H
+
):  372.9382. 
Found: 372.9385. 
 
Synthesis of 2-((6-bromo-7-chloroquinazolin-4-
yl)amino)ethanol. N-(4-Bromo-5-chloro-2-(4,5-dihydrooxazol-
2-yl)phenyl)-2,2,2-trifluoroacetamide (2.29 g, 6.16 mmol) was 
dissolved in ethanol (62 mL), NaOH pellets (4.93 g, 123 mmol) 
were added and the reaction mixture was allowed to stir at 
room temperature. The reaction was monitored by TLC 
analysis until complete conversion of the starting material was 
observed; upon completion the solvent was removed in vacuo. 
The residue was dissolved in water and ethyl acetate, and 
transferred to a separating funnel. The layers were partitioned, 
followed by further extraction of the aqueous layer with ethyl 
acetate. The combined organics were then washed with brine, 
followed by drying over anhydrous MgSO4, filtered and the 
solvent removed in vacuo. The residue was then dissolved in 
ethanol (60 mL) and formamidine acetate (1.88 g, 18.1 mmol) 
was added, and the mixture heated at reflux for 1 hour.  After 
cooling to room temperature, the reaction mixture was dry 
loaded onto silica gel and purified by flash column 
chromatography on silica gel eluting with dichloromethane 
and methanol (0 to 15% methanol) to afford the quinazoline 
product as a colourless solid (1.32 g, 73%). M.p.: 220  ? 221 °C; 
1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ ? ? ? ? ? ?, ?Ɛ ? ? ? ? ? ? ? ?, ?ĂƉƉ ?Ě ?J
= 5.0 Hz), 8.47 (1H, s), 7.90 (1H, s), 4.82 (1H, t, J = 5.0 Hz), 3.65 
 ? 3.53 (4H, m); 13C NMR (100.6 MHz, DMSO-d6 ? ?ɷ ? ? ? ? ? ? ? ? ? ? ? ?
149.0, 137.0, 128.4, 128.3, 117.8, 115.0, 58.9, 43.5; FTIR: vmax
 
(neat) 3285 (w), 2986 (w), 1684 (m), 1587 (s), 1543 (m), 1442 
(m), 1412 (m), 1059 (s); HRMS calculated for C10H10
81
Br
35
ClN3O 
(ES
+
)(+H
+
): 303.9668. Found: 303.9666. 
 
Synthesis of 6-bromo-7-chloroquinazolin-4(3H)-one (4b). 2-
((6-bromo-7-chloroquinazolin-4-yl)amino)ethanol (258 mg, 
0.852 mmol) was suspended in 6 M HCl aq. (6.5 mL) in a round 
bottomed flask equipped with reflux condenser, and heated to 
100  ? 105 °C for a period of 2 hours. The reaction was then 
allowed to cool to room temperature, and further cooled to 0 
°C with an ice/water bath. The reaction mixture was basified to 
pH 11 with aqueous NaOH solution (10% w/v) and allowed to 
stir for 15 minutes. The colourless precipitate was collected by 
vacuum filtration, washing with a little ice cold water. The 
precipitate was then dried further to afford the quinazolinone 
product as a colourless solid (202 mg, 91%). M.p.: > 250 °C; 
1
H 
NMR (400 MHz, DMSO-d
6 ? ? ɷ  ? ? ? ?  ? ?, ? Ɛ ? ?  ? ? ? ?  ? ?, ? Ɛ ? ?  ? ? ? ?
(1H, s); 
13
C NMR (100.6 MHz, DMSO-d
6 ? ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
138.9, 130.6, 128.5, 122.8, 119.4; FTIR: vmax/ cm
-1 
(neat) 3043 
(w), 3006 (w), 1721 (m), 1660 (s), 1610 (s), 1442 (s), 1254 (s), 
899 (s); HRMS calculated for C8H5
81
Br
35
ClN2O (ES
+
)(+H
+
): 
260.9246. Found: 260.9252. 
 
General Procedure for the Synthesis of febrifugine analogs. 
Potassium carbonate (1.5 eq.) was added to a suspension of 
quinazolinone (1.0 eq.) in MeCN (0.1 M) and the mixture was 
heated at reflux. A solution of benzyl 2-(2-(chloromethyl)allyl)-
3-hydroxypyrrolidine-1-carboxylate (1.0 eq.) in MeCN (0.3 M) 
was added dropwise to the reaction mixture and the reaction 
was left to stir for 16 h. After completion, aqueous NH4Cl was 
added and the product was extracted with ethyl acetate. The 
organic layers were dried over MgSO4 and the solvent was 
removed under reduced pressure to afford the crude product. 
The crude residue was purified via flash column 
chromatography eluting with CH2Cl2 : MeOH (8 : 2) to afford 
the corresponding alkene intermediates, which were subjected 
to the subsequent step following 
1
H NMR analysis (see SI). 
OsO4 (few crystals) was added to a suspension of the alkene 
substrate (1.0 eq.) and NaIO4 (2.0 eq.) in THF (0.1 M) and 
water (0.2 M), and the solution was left to stir for 16 h. After 
completion, a saturated aqueous solution of Na2S2O5 was 
added, transferred to a separating funnel and extracted with 
ethyl acetate. The combined organic layers were dried over 
anhydrous MgSO4 and the solvent was removed under 
reduced pressure to afford the crude product. The crude 
residue was purified via flash column chromatography eluting 
with CH2Cl2 : MeOH (8 : 2) to afford the corresponding ketone.  
Trans substrates: To the ketone substrate (1.0 eq.) in a round 
bottom flask was added methanol (0.2 M) and HBr (33 wt% in 
AcOH) (100 eq.) at 0 °C. The mixture was stirred for 30 mins 
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and after completion the solvent was removed in vacuo, 
purification by recrystallization from ethanol afford the 
corresponding products. 
Cis substrates: To the ketone substrate (1.0 eq.) in a round 
bottom flask was added dichloromethane (0.2 M) and HBr (33 
wt% in AcOH) (100 eq.) at 0 °C. The mixture was stirred for 30 
mins and after completion, aqueous NaOH was added, 
transferred to a separating funnel and extracted with ethyl 
acetate (2 x 20 mL). The combined organic layers were dried 
over anhydrous MgSO4 and the solvent removed under 
reduced pressure to afford a crude residue, which was purified 
by flash column chromatography eluting CH2Cl2 : MeOH (8 : 2) 
to afford the corresponding products. 
 
trans-7-Bromo-6-chloro-3-(3-(3-hydroxypiperidine-2-yl)-2-
oxopropyl)quinazolin-4(3H)-one hydrobromide (trans-5a). 7-
Bromo-6-chloroquinazolin-4(3H)-one (4a) (50 mg, 0.19 mmol), 
K2CO3 (40 mg, 0.28 mmol) and trans-3a (62 mg, 0.92 mmol) 
were subjected to the general conditions for 16 h to afford the 
trans-alkene intermediate as a yellow oil (98 mg, 93%).
 
trans-
Alkene intermediate (88 mg, 0.16 mmol) was subjected to the 
general conditions to afford trans-5a as a colorless solid (55 
mg, 70%). M.p.: > 250 °C; 
1
H NMR (400 MHz, MeOD-d
4 ? ?ɷ ? ? ? ?
(1H, s), 8.22 (1H, s), 8.12 (1H, s), 5.11 (1H, d, J = 17.5 Hz), 5.02 
(1H, d, J = 17.5 Hz), 3.70 - 3.60 (1H, m), 3.55 - 3.45 (2H, m), 
3.40 (1H, d, J = 5.0 Hz), 3.05 (1H, dd, J = 15.0, 4.0 Hz), 3.00 (1H, 
dd, J = 15.0, 4.0 Hz), 2.15 - 2.00 (2H, m), 1.85 - 1.75 (1H, m), 
1.65 - 1.55 (1H, m); 
13
C NMR (101 MHz, MeOD-d
4 ? ɷ202.2, 
161.0, 150.5, 148.4, 134.6, 133.5, 129.5, 128.4, 123.2, 68.2, 
58.1, 55.8, 44.9, 39.9, 31.5, 21.4 ?&d/Z ?ʆmax 3290 (w), 2943 (w), 
1715 (m), 1677 (s), 1598 (s), 1080 (s); HRMS calculated for 
C16H17
79
Br
35
ClN3O3 (ES
+
)(+H
+
): 416.0193. Found: 416.0193.   
 
trans-6-Bromo-7-chloro-3-(3-(3-hydroxypiperidine-2-yl)-2-
oxopropyl)quinazolin-4(3H)-one hydrobromide (trans-5b). 6-
Bromo-7-chloroquinazolin-4(3H)-one (4b) (77 mg, 0.30 mmol), 
K2CO3 (62 mg, 0.45 mmol) and trans-3a (96 mg, 0.30 mmol) 
were subjected to the general conditions for 16 h to afford the 
trans-alkene intermediate as a yellow oil (145 mg, 89%).
 
trans-
Alkene intermediate (102 mg, 0.186 mmol) was subjected to 
the general conditions to afford trans-ketone intermediate as 
a colorless oil (64 mg, 64%). trans-Ketone intermediate (60 mg, 
0.11 mmol) was subjected to the general conditions to afford 
trans-5b as a colorless solid (27 mg, 50%). M.p.: 240 °C 
(decomp.); 
1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ 8.38 (1H, s), 8.29 
(1H, s), 8.03 (1H, s), 5.57 (1H, d, J = 5.5 Hz), 5.12 (1H, d, J = 18.0 
Hz), 5.06 (1H, d, J = 18.0 Hz), 3.56  ? 3.42 (1H, m), 3.27  ? 3.11 
(3H, m), 2.90 (2H, dd, J = 17.5, 6.0 Hz), 1.98  ? 1.88 (1H, m), 
1.86  ? 1.76 (1H, m), 1.70  ? 1.54 (1H, m), 1.52  ? 1.40 (1H, m); 
13
C NMR (100.6 MHz, DMSO-d
6 ? ?ɷ 200.8, 158.5, 149.8, 147.9, 
139.4, 130.8, 128.8, 121.5, 120.1, 66.8, 56.1, 54.4, 43.0, 30.5, 
20.2  ? one peak not resolved due to overlap with DMSO-d6; 
FTIR: vmax/ cm
-1
 (neat) 2924 (w), 1724 (w), 1673 (s), 1606 (s), 
1442 (s), 1358 (s), 1090 (s), 1070 (s); HRMS calculated for 
C16H18
81
Br
35
ClN3O3 (ES
+
)(+H
+
): 416.0193. Found: 416.0200. 
 
trans-6-Chloro-3-(3-(3-hydroxypiperidin-2-yl)-2-
oxopropyl)pyrido[3,4-d]pyrimidin-4(3H)-one dihydrobromide 
(trans-5c). 6-Chloropyrido[3,4-d]pyrimidin-4(3H)-one (4c) (100 
mg, 0.550 mmol), K2CO3 (114 mg, 0.826 mmol) and trans-3a 
(178 mg, 0.55 mmol) were subjected to the general conditions 
for 16 h to afford the trans-alkene intermediate as a colourless 
oil (144 mg, 56%).
 
trans-Alkene intermediate (140 mg, 0.298 
mmol) was subjected to the general conditions to afford trans-
ketone intermediate as a colorless oil (43 mg, 31%). trans-
Ketone intermediate (40 mg, 0.085 mmol) was subjected to 
the general conditions to afford trans-5c as a colorless 
amorphous solid (15 mg, 36%). 
1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ 
9.00 (1H, s), 8.35 (1H, s), 8.04 (1H, s), 5.57 (1H, d, J = 5.5 Hz), 
5.15 (1H, d, J = 18.0 Hz), 5.09 (1H, d, J = 18.0 Hz), 3.55  ? 3.42 
(1H, m), 3.30  ? 3.11 (2H, m), 2.97  ? 2.81 (2H, m), 1.98  ? 1.86 
(1H, m), 1.89  ? 1.75 (1H, m), 1.69  ? 1.54 (1H, m), 1.52  ? 1.37 
(1H, m); 
13
C NMR (100.6 MHz, DMSO-d
6 ? ?ɷ 200.6, 158.2, 151.3, 
150.1, 146.9, 141.9, 129.1, 118.6, 66.8, 56.1, 54.6, 43.0, 30.5, 
20.2  ? one peak not resolved due to overlap with DMSO-d6; 
FTIR: vmax (neat) 2936 (w), 1738 (m), 1694 (s), 1600 (s), 1436 
(s), 1372 (s), 1288 (m), 1073 (s); HRMS calculated for 
C15H18
35
ClN4O3 (ES
+
)(+H
+
): 337.1062. Found: 337.1063. 
 
trans-3-(3-(3-Hydroxypiperidin-2-yl)-2-oxopropyl)-6,7-bis(2-
methoxyethoxy)quinazolin-4(3H)-one hydrobromide (trans-
5d). 6,7-Bis(2-methoxyethoxy) quinazolin-4(3H)-one (4d) (20 
mg, 0.06 mmol), K2CO3 (14 mg, 0.10 mmol) and trans-3a (22 
mg, 0.06 mmol) were subjected to the general conditions for 
16 h to afford the trans-alkene intermediate as a colourless oil 
(28 mg, 71%).
 
trans-Alkene intermediate (28 mg, 0.04 mmol) 
was subjected to the general conditions to afford trans-5d as a 
colorless solid (20 mg, 80%). M.p.: > 250 °C; 
1
H NMR (400 MHz, 
MeOD-d
4 ? ?ɷ ? ? ? ? ? ?, ?Ɛ ? ? ? ? ? ? (1H, s), 7.27 (1H, s), 5.33 (1H, d, 
J = 18.0 Hz), 5.26 (1H, d, J = 18.0 Hz), 4.40 - 4.30 (4H, m), 3.90 - 
3.80 (4H, m), 3.70 - 3.60 (1H, m), 3.52 - 3.45 (2H, m), 3.43 (6H, 
s), 3.41 (1H, d, J = 5.0 Hz), 3.08 (1H, dd, J = 15.0, 4.0 Hz), 3.00 
(1H, dd, J = 15.0, 4.0 Hz), 2.15 - 2.00 (2H, m), 1.85 - 1.75 (1H, 
m), 1.67 - 1.57 (1H, m); 
13
C NMR (101 MHz, MeOD-d
4 ? ?ɷ ? ? ? ? ? ?
157.5, 156.3, 150.6, 149.1, 134.9, 113.5, 107.5, 102.5, 70.5, 
70.3, 69.5, 69.0, 67.0, 58.1, 58.0, 56.6, 55.2, 43.4, 39.0, 30.0, 
 ? ? ? ? ?&d/Z ?ʆmax 3346 (w), 2926 (w), 1659 (s), 1705 (s), 1604 (s), 
1382 (s), 987 (s); HRMS calculated for C22H31N3O7 (ES
+
)(+H
+
): 
450.2235. Found: 450.2237. 
 
trans-6-Bromo-3-(3-(3-hydroxypiperidin-2-yl)-2-
oxopropyl)quinazolin-4(3H)-one hydrobromide (trans-5e). 6-
Bromoquinazolin-4(3H)-one (4e) (139 mg, 0.618 mmol), K2CO3 
(128 mg, 0.928 mmol) and trans-3a (200 mg, 0.618 mmol) 
were subjected to the general conditions for 16 h to afford the 
trans-alkene intermediate as a colourless oil (229 mg, 72%).
 
trans-Alkene intermediate (229 mg, 0.447 mmol) was 
subjected to the general conditions to afford trans-ketone 
intermediate as a colorless oil (140 mg, 61%). trans-Ketone 
intermediate (100 mg, 0.085 mmol) was subjected to the 
general conditions to afford trans-5e as a colorless solid (30 
mg, 33%). M.p.: 221 - 222 °C; 
1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ
8.69 (2H, s), 8.28 (1H, s), 8.23 (1H, d, J = 2.5 Hz), 8.03 (1H, dd, J 
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= 8.5, 2.5 Hz), 7.73  ? 7.66 (1H, m), 5.13 (1H, d, J = 18.0 Hz), 
5.08 (1H, d, J = 18.0 Hz), 3.56  ? 3.47 (1H, m), 3.39  ? 3.29 (1H, 
m), 3.24 (1H, dd, J = 17.5, 5.5 Hz), 3.17 (1H, d, J = 12.5 Hz), 2.92 
(2H, dd, J = 17.5, 6.0 Hz), 1.98  ? 1.90 (1H, m), 1.87  ? 1.77 (1H, 
m), 1.70  ? 1.58 (1H, m), 1.53  ? 1.40 (1H, m); 13C NMR (101 
MHz, DMSO-d
6 ? ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ?.9, 137.5, 129.8, 
128.1, 122.9, 119.8, 66.7, 56.1, 54.4, 43.0, 39.4, 30.5, 20.1; 
&d/Z ? ʆmax 3088 (w), 2671 (w), 1713 (m), 1631 (w), 1522 (m), 
1099 (m); HRMS calculated for C16H19
79
BrN3O3 (ES+)(+H+): 
380.0604. Found: 380.0613. 
 
3-(3-(3-Hydroxypiperidin-2-yl)-2-oxopropyl)quinazolin-4(3H)-
one hydrobromide (trans-5f). Quinazolin-4(3H)-one (4f) (50 
mg, 0.03 mmol), K2CO3 (70 mg, 0.05 mmol) and trans-3a (110 
mg, 0.03 mmol) were subjected to the general conditions for 
16 h to afford the trans-alkene intermediate as a yellow oil 
(113 mg, 77%).
 
trans-Alkene intermediate (113 mg, 0.26 mmol) 
was subjected to the general conditions to afford trans-5f as a 
colorless solid (88 mg, 89%). M.p.: > 250 °C; 
1
H NMR (400 MHz, 
MeOD-d
4 ? ?ɷ  ? ? ? ?  ? ?, ?Ɛ ? ? ? ? ? ?- 8.30 (1H, m), 8.10 - 7.95 (1H, 
m), 7.85 - 7.70 (2H, m), 5.30 (1H, d, J = 17.5 Hz), 5.22 (1H, d, J = 
17.5 Hz), 3.75 - 3.65 (1H, m), 3.55 - 3.50 (2H, m), 3.45 (1H, d, J 
= 4.5 Hz), 3.05 (1H, dd, J = 15.0, 4.0 Hz), 3.01 (1H, dd, J = 15.0, 
4.0 Hz), 2.16 - 2.04 (2H, m), 1.88 - 1.76 (1H, m), 1.68 - 1.60 (1H, 
m); 
13
C NMR (101 MHz, MeOD-d
4 ? ? ɷ  ? ? ? ? ? ?  ? ? ? ? ? ?  ? ? ? ? ? ?
147.4, 138.4, 136.8, 129.5, 127.5, 120.7, 66.9, 56.6, 55.2, 43.5, 
 ? ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?&d/Z ?ʆmax 3329 (w), 2924 (w), 1704 (s), 1660 
(s), 1507 (s), 1028 (s); HRMS calculated for C16H19N3O3 
(ES
+
)(+H
+
): 302.3404. Found: 302.3403. 
 
cis-7-Bromo-6-chloro-3-((6-hydroxyoctahydro-1H-
cyclopenta[b]pyridine-6-yl)methyl)quinazolin-4(3H)-one (cis-
6) and 7-bromo-6-chloro-3-(4-(3,4-dihydro-2H-pyrrol-5-yl)-2-
oxobutyl)quinazolin-4(3H)-one (7). 7-Bromo-6-
chloroquinazolin-4(3H)-one (4a) (50 mg, 0.19 mmol), K2CO3 (40 
mg, 0.28 mmol) and cis-3a (62 mg, 0.92 mmol) were subjected 
to the general conditions for 16 h to afford the cis-alkene 
intermediate as a colourless oil (88 mg, 85%).
 
cis-Alkene 
intermediate (88 mg, 0.16 mmol) was subjected to the general 
conditions to afford cis-6 as a colorless solid (10 mg, 16%) and 
7 as a colorless oil (25 mg, 40%). cis-6: 
1
H NMR (400 MHz, 
CDCl3 ? ?ɷ ? ? ? ? ? ?, ?Ɛ ? ? ? ? ? ? ? ?, ?Ɛ ? ? ? ? ? ? ? ?, ?Ɛ ? ? ? ? ? ?, Ě ?J = 
14.0 Hz), 4.19 (1H, d, J = 14.0 Hz), 3.94 - 3.91 (1H, m), 3.34 - 
3.32 (1H, m), 3.04 - 3.05 (2H, m), 2.56 - 2.53 (1H, m), 2.20 - 
2.05 (1H, m), 1.90 - 1.80 (2H, m), 1.65 - 1.55 (2H, m), 1.50 - 
1.45 (2H, m); 
13
C NMR (101 MHz, CDCl3 ? ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
133.4, 132.8, 129.5, 128.0, 122.1, 105.3, 78.0, 55.8, 50.3, 44.6, 
43.6, 26.9, 20.2 ?&d/Z ?ʆmax 3294 (w), 2944 (w), 1672 (s), 1609 
(s), 1473 (s); HRMS calculated for C16H17
79
Br
35
ClN3O3 (ES
+
)(+H
+
): 
416.1504. Found: 416.1495. 7: 
1
H NMR (400 MHz, CDCl3 ? ? ɷ 
8.32 (1H, s), 8.02 (1H, s), 7.87 (1H, s), 4.97 (2H, s), 3.87  ? 3.69 
(2H, m), 2.88 (2H, t, J = 6.5 Hz), 2.67 (2H, t, J = 6.5 Hz), 2.46 
(2H, t, J = 8.0 Hz), 2.01  ? 1.80 (2H, m); 13C NMR (101 MHz, 
CDCl3 ? ?ɷ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?  ?      ?
127.8, 122.1, 60.6, 54.7, 38.0, 35.8, 27.9, 22.9 ?&d/Z ?ʆmax 2918 
(w), 1722 (w), 1676 (s), 1608 (s), 1447 (s), 1354 (s); HRMS 
calculated for C16H16
79
Br
37
ClN3O2 (ES
+
)(+H
+
): 398.0087. Found: 
398.0085. 
 
Potassium N,N-dimethyltrifluoroboratomethylamine. 
Potassium bromomethyltrifluoroborate (1.00 g, 4.98 mmol) 
was added to neat dimethylamine in THF (20 mL) at RT, heated 
at 80 °C for 30 minutes and then concentrated in vacuo. The 
product was dissolved in a solution of acetone (150 mL) and 
K2CO3 (689 mg, 4.98 mmol) and stirred for 30 minutes. The 
insoluble salts were filtered off, and the filtrate was 
concentrated in vacuo. The crude solid was dissolved in a 
minimal amount of hot acetone, and diethyl ether was added 
dropwise leading to precipitation of the product. The product 
was then filtered and collected and dried under vacuum. The 
product was afforded as a colourless solid (320 mg, 39%). 
M.p.: 65  ? 66 °C; 1H NMR (400 MHz, DMSO-d6 ? ?ɷ 2.63 (6H, s), 
1.98  ? 1.88 (2H, m); 13C NMR (100.6 MHz, DMSO-d6 ? ? ɷ 52.0 
(br), 45.2; 
19
F NMR (376.5 MHz, DMSO-d
6 ? ? ɷ  ? 138.5; 11B 
(128.4 MHz, DMSO-d
6 ? ?ɷ 2.5; FTIR: vmax (neat) 3215 (w), 1483 
(w), 1463 (w), 1256 (m), 1023 (s), 952 (s); HRMS calculated for 
C3H8
11
BF3N (M
-
): 126.0707. Found: 126.0713. 
 
General procedure for synthesis of amino methyl 
quinazolinones (9a ʹ c). Step 1: To a round bottomed flask 
equipped with a reflux condenser was added quinazoline (1.0 
eq.), aminomethyl-BF3K (1.1 eq.), Cs2CO3 (3.0 eq.) and 
PdXPhosG2 (10 mol %). The reaction vessel was evacuated and 
refilled with N2 (3 cycles). The degassed solvent mixture 
THF/H2O (10:1) was then added via syringe, and the reaction 
was heated at reflux for 16 hours. The reaction was then 
cooled to room temperature, and transferred to a larger round 
bottomed flask, rinsing with dichloromethane and methanol. 
The solvent was then removed in vacuo to afford the crude 
residue. The crude reaction mixture was purified by flash 
column chromatography on silica gel eluting with 
dichloromethane and methanol (0 to 20% methanol) to afford 
the corresponding products. Step 2: The purified Suzuki 
product was then suspended in 6 M HCl aq. (100 eq.) in a 
round bottomed flask equipped with reflux condenser, and 
heated to 100  ? 105 °C for a period of 2 hours. The reaction 
was then allowed to cool to room temperature, and further 
cooled to 0 °C with an ice/water bath. The reaction mixture 
was basified to pH 11 with aqueous NaOH solution (10% w/v) 
and allowed to stir for 15 minutes. The reaction mixture was 
then concentrated to remove H2O. The reaction mixture was 
then dry loaded onto silica and purified by flash column 
chromatography, eluting with dichloromethane and 10% 
methanol to afford the quinazolinone product. 
 
6-Chloro-7-((diethylamino)methyl)quinazoline-4(3H)-one 
(9a). Step 1: Following the general procedure, using 2-((7-
bromo-6-chloroquinazolin-4-yl)amino)ethanol (300 mg, 0.992 
mmol), potassium N,N-diethyltrifluoroboratomethylamine 
(210 mg, 1.09 mmol), Cs2CO3 (970 mg, 2.97 mmol), PdXPhosG2 
(78 mg, 10 mol %, 0.099 mmol) and THF/H2O (10:1, 4 mL) the 
product was afforded as a cream solid (166 mg, 54%). M.p.: 62 
 ? 63 °C; 1H NMR (400 MHz, DMSO-d6 ? ?ɷ 8.44 (1H, s), 8.43 (1H, 
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s), 8.39  ? 8.26 (1H, m), 7.80 (1H, s), 4.88  ? 4.76 (1H, m), 3.71 
(2H, s), 3.65  ? 3.52 (4H, m), 2.56 (4H, q, J = 7.0 Hz), 1.01 (6H, t, 
J = 7.0 Hz); 
13
C NMR (100.6 MHz, DMSO-d
6 ? ? ɷ 158.7, 155.5, 
147.9, 142.3, 130.0, 128.6, 123.0, 114.6, 59.1, 54.5, 46.8, 43.4, 
11.8; FTIR: vmax (neat) 3302 (m), 2973 (w), 1587 (m), 1547 (m), 
1416 (m), 1278 (m), 1067 (m), 748 (s); HRMS calculated for 
C15H22
35
ClN4O (ES
+
)(+H
+
): 309.1477. Found: 309.1484. Step 2: 
Following the general procedure, using 2-((6-chloro-7-
((diethylamino)methyl)quinazoline-4-yl)amino)ethanol (100 
mg, 0.323 mmol) and 6 M HCl aq. (2.5 mL) the product was 
afforded as a beige solid (60 mg, 70%). M.p.: 139  ? 140 °C; 1H 
NMR (400 MHz, MeOD-d
4 ? ? ɷ 8.10 (1H, s), 8.08 (1H, s), 7.91 
(1H, s), 3.80 (2H, s), 2.65 (4H, q, J = 7.0 Hz), 1.10 (6H, t, J = 7.0 
Hz); 
13
C NMR (100.6 MHz, MeOD-d
4 ? ? ɷ 162.1, 148.4, 146.9, 
146.1, 133.8, 129.7, 127.3, 123.5, 56.0, 48.6, 12.1; FTIR: vmax 
(neat) 2970 (w), 1698 (s), 1613 (s) 1432 (m), 1379 (m), 1258 
(s), 922 (s), 751 (s); HRMS calculated for C13H17
35
ClN3O 
(ES
+
)(+H
+
): 266.1055. Found: 266.1055. 
 
6-Chloro-7-((dimethylamino)methyl)quinazoline-4(3H)-one 
(9b). Step 1: Following the general procedure, using 2-((7-
bromo-6-chloroquinazolin-4-yl)amino)ethanol (200 mg, 0.661 
mmol), potassium N,N-dimethyltrifluoroboratomethylamine 
(120 mg, 0.727 mmol), Cs2CO3 (645 mg, 1.98 mmol), 
PdXPhosG2 (52 mg, 10 mol %, 0.066 mmol) and THF/H2O 
(10:1, 2.6 mL) the product was afforded as a yellow 
amorphous solid (126 mg, 68%). 
1
H NMR (400 MHz, MeOD-d
4
): 
ɷ 8.44 (1H, s), 8.27 (1H, s), 7.79 (1H, s), 3.82 (2H, t, J = 5.5 Hz), 
3.79  ? 3.68 (4H, m), 2.37 (6H, s); 13C NMR (100.6 MHz, MeOD-
d
4 ? ? ɷ 160.8, 156.6, 148.3, 142.3, 133.3, 130.1, 124.3, 116.5, 
61.5, 61.2, 45.6, 44.8; FTIR: vmax (neat) 3436 (w), 2986 (w), 
1590 (w), 1274 (m), 1261 (m); HRMS calculated for 
C13H18
35
ClN4O (ES
+
)(+H
+
): 281.1164. Found: 281.1162. Step 2: 
Following the general procedure, using 2-((6-chloro-7-
((dimethylamino)methyl)quinazoline-4-yl)amino)ethanol (121 
mg, 0.431 mmol)  and 6 M HCl aq. (3.4 mL) the product was 
afforded as a colourless solid (53 mg, 52%). M.p.: 161  ? 162 °C; 
1
H NMR (400 MHz, MeOD-d
4 ? ?ɷ 8.15 (1H, s), 8.08 (1H, s), 7.80 
(1H, s), 3.70 (2H, s), 2.34 (6H, s); 
13
C NMR (100.6 MHz, MeOD-
d
4 ? ? ɷ 162.1, 148.5, 147.0, 144.3, 134.3, 130.4, 127.5, 123.9, 
61.4, 45.7; FTIR: vmax (neat) 2973 (w), 1691 (m), 1614 (m), 1258 
(m), 902 (m), 764 (s); HRMS calculated for C11H13
35
ClN3O 
(ES
+
)(+H
+
): 238.0742. Found: 238.0750. 
 
6-Chloro-7-((morpholinomethyl)methyl)quinazoline-4(3H)-
one (9c). Step 1: Following the general procedure, using 2-((7-
bromo-6-chloroquinazolin-4-yl)amino)ethanol (200 mg, 0.661 
mmol), potassium 4-trifluoroboratomethyl-morpholine (140 
mg, 0.727 mmol), Cs2CO3 (645 mg, 1.98 mmol), PdXPhosG2 (52 
mg, 10 mol %, 0.066 mmol) and THF/H2O (10:1, 2.6 mL) the 
product was afforded as a colourless solid (161 mg, 76%). 
M.p.: 76  ? 77 °C; 1H NMR (400 MHz, MeOD-d4 ? ?ɷ 8.41 (1H, s), 
8.20 (1H, s), 7.83 (1H, s), 3.82 (2H, t, J = 5.5 Hz), 3.77  ? 3.69 
(8H, m), 2.62  ? 2.54 (4H, m); 13C NMR (100.6 MHz, MeOD-d4 ? ?ɷ 
160.8, 156.4, 148.3, 142.5, 133.1, 129.2, 124.1, 116.2, 68.0, 
61.2, 60.7, 54.8, 44.8; FTIR: vmax (neat) 3319 (m), 3120 (m), 
2926 (m), 2832 (m), 1587 (s), 1543 (s), 1429 (s), 1409 (s), 1332 
(s), 1117 (s), 1060 (s), 862 (s); HRMS calculated for 
C15H20
35
ClN4O2 (ES
+
)(+H
+
): 323.1269. Found: 323.1276. Step 2: 
Following the general procedure, using 2-((6-chloro-7-
(morpholinomethyl)quinazoline-4-yl)amino)ethanol (128 mg, 
0.397 mmol) and 6 M HCl aq. (3.0 mL) the product was 
afforded as a colourless solid (63 mg, 57%).M.p.: 187  ? 188 °C; 
1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ 12.37 (1H, s), 8.11 (1H, s), 8.05 
(1H, s), 7.78 (1H, s), 3.67 (2H, s), 3.64  ? 3.58 (4H, m), 2.49  ? 
2.46 (4H, m); 
13
C NMR (100.6 MHz, DMSO-d
6 ? ?ɷ 159.6, 147.4, 
146.0, 142.1, 131.4, 128.9, 125.8, 122.5, 66.2, 59.0, 53.3; FTIR: 
vmax (neat) 3020 (m), 2963 (m), 1698 (s), 1674 (s), 1607 (s), 
1426 (m), 1258 (m), 1114 (s), 865 (m); HRMS calculated for 
C13H15
35
ClN3O2 (ES
+
)(+H
+
): 280.0847. Found: 280.0851. 
 
General Procedure for the Synthesis of aminomethyl 
halofuginone analogs (10a-c). Potassium carbonate (1.5 eq.) 
was added to a suspension of quinazolinone (1.0 eq.) in MeCN 
(0.1 M) and the mixture was heated at reflux. A solution of 
benzyl 2-(2-(chloromethyl)allyl)-3-hydroxypyrrolidine-1-
carboxylate (1.0 eq.) in MeCN (0.3 M) was added dropwise to 
the reaction mixture and the reaction was left to stir for 16 h. 
After completion, aqueous NH4Cl was added and the product 
was extracted with ethyl acetate. The organic layers were 
dried over MgSO4 and the solvent was removed under reduced 
pressure to afford the crude product. The crude residue was 
purified via flash column chromatography eluting with CH2Cl2 : 
MeOH (8 : 2) to afford the corresponding alkene 
intermediates, which were subjected to the subsequent step 
following 
1
H NMR analysis (see SI). Alkene substrate (1.0 eq.) 
and TFA (1.1 eq.) in THF (0.1 M) and water (0.2 M) were stirred 
for 30 minutes prior to the addition of OsO4 (few crystals) and 
NaIO4 (2.0 eq.). The solution was left to stir at RT for 16 h. 
After completion, a saturated aqueous solution of Na2S2O5 was 
added, transferred to a separating funnel and extracted with 
ethyl acetate. The combined organic layers were dried over 
anhydrous MgSO4 and the solvent was removed under 
reduced pressure to afford the crude product. The crude 
residue was purified via flash column chromatography eluting 
with CH2Cl2 : MeOH (8 : 2) to afford the corresponding ketone. 
To the ketone substrate (1.0 eq.) in a round bottom flask was 
added methanol (0.2 M) and HBr (33 wt% in AcOH) (100 eq.) at 
0 °C. The mixture was stirred for 30 mins and after completion 
the solvent was removed in vacuo, purification by 
recrystallization from ethanol afford the corresponding 
products. 
 
trans-6-Chloro-7-((diethylamino)methyl)-3-(3-(3-
hydroxypiperidin-2-yl)-2-oxopropyl)quinazoline-4(3H)-one 
dihydrobromide (trans-10a). 6-Chloro-7-
((diethylamino)methyl)quinazoline-4(3H)-one (9a) (55 mg, 0.21 
mmol), K2CO3 (43 mg, 0.31 mmol) and trans-3a (69 mg, 0.21 
mmol) were subjected to the general conditions for 16 h to 
afford the trans-alkene intermediate as a colorless oil (97 mg, 
84%). trans-Alkene intermediate (111 mg, 0.200 mmol) was 
subjected to the general conditions to afford trans-ketone 
intermediate as a colorless oil (65 mg, 58%). trans-Ketone 
intermediate (49 mg, 0.088 mmol) was subjected to the 
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general conditions to afford trans-10a as a colorless solid (18 
mg, 35%). M.p.: 178  ? 179 °C; 1H NMR (400 MHz, DMSO-d6 ? ?ɷ 
8.32 (1H, s), 8.22 (1H, s), 8.19 (1H, s), 5.16 (1H, d, J = 18.0 Hz), 
5.11 (1H, d, J = 18.0 Hz), 4.62 (2H, d, J = 5.5 Hz), 3.56  ? 3.31 
(peak not fully resolved due to overlap with residual H2O), 3.29 
 ? 3.13 (6H, m), 2.92 (2H, dd, J = 17.5 Hz, 6.0 Hz), 1.97  ? 1.88 
(1H, m), 1.87  ? 1.78 (1H, m), 1.70  ? 1.56 (1H, m), 1.50  ? 1.39 
(1H, m), 1.29 (6H, t, J = 7.0 Hz); 
13
C NMR (100.6 MHz, DMSO-
d
6 ? ? ɷ 201.1, 159.1, 149.7, 147.0, 135.3, 133.2, 133.0, 127.2, 
123.7, 67.4, 56.6, 55.0, 52.6, 47.5, 43.4, 31.0, 20.6, 9.0  ? one 
peak not resolved due to overlap with DMSO-d
6
; FTIR: vmax 
(neat) 3387 (s), 2943 (m), 1733 (s), 1677 (s), 1605 (s), 1472 (s), 
1397 (s), 1363 (s), 1080 (m); HRMS calculated for 
C21H30
35
ClN4O3 (ES
+
)(+H
+
): 421.2001. Found: 421.2009. 
 
trans-6-Chloro-7-((dimethylamino)methyl)-3-(3-(3-
hydroxypiperidin-2-yl)-2-oxopropyl)quinazoline-4(3H)-one 
dihydrobromide (trans-10b). 6-Chloro-7-
((dimethylamino)methyl)quinazoline-4(3H)-one (9b) (51 mg, 
0.21 mmol), K2CO3 (43 mg, 0.31 mmol) and trans-3a (69 mg, 
0.21 mmol) were subjected to the general conditions for 16 h 
to afford the trans-alkene intermediate as a colorless oil (83 
mg, 74%). trans-Alkene intermediate (81 mg, 0.15 mmol) was 
subjected to the general conditions to afford trans-ketone 
intermediate as a colorless oil (59 mg, 73%). trans-Ketone 
intermediate (54 mg, 0.10 mmol) was subjected to the general 
conditions to afford trans-10b as a pale orange solid (24 mg, 
43%). M.p.: 221 °C (decomp.); 
1
H NMR (400 MHz, DMSO-d
6 ? ?ɷ 
8.33 (1H, s), 8.21 (1H, s), 8.18 (1H, s), 5.16 (1H, d, J = 18.5 Hz), 
5.11 (1H, d, J = 18.5 Hz), 4.64 (2H, app s), 3.58  ? 3.49 (1H, m), 
3.25 (1H, d, J = 6.0 Hz), 3.47  ? 3.31 (peak not fully resolved due 
to overlap with residual H2O), 3.22  ? 3.13 (2H, m), 2.98  ? 2.84 
(8H, m), 1.97  ? 1.90 (1H, m), 1.87  ? 1.78 (1H, m), 1.71  ? 1.59 
(1H, m), 1.52  ? 1.40 (1H, m); 13C NMR (100.6 MHz, DMSO-d6 ? ?ɷ 
200.6, 158.7, 149.2, 146.6, 134.8, 132.6, 132.4, 126.7, 123.2, 
66.9, 56.3, 56.2, 54.5, 43.0, 42.6, 30.5, 20.2  ? one peak not 
resolved due to overlap with DMSO-d
6
; FTIR: vmax (neat) 3299 
(w), 3011 (w), 2924 (w), 1720 (m), 1678 (s), 1610 (m), 1472 
(m), 1325 (m), 1278 (m), 1093 (m); HRMS calculated for 
C19H26
35
ClN4O3 (ES
+
)(+H
+
): 393.1688. Found: 393.1699. 
 
trans-6-Chloro-3-(3-(3-hydroxypiperidin-2-yl)-2-oxopropyl)-7-
(morpholinomethyl)quinazoline-4-(3H)-one dihydrobromide 
(trans-10c). 6-Chloro-7-
((morpholinomethyl)methyl)quinazoline-4(3H)-one (9c) (50 
mg, 0.18 mmol), K2CO3 (25 mg, 0.27 mmol) and trans-3a (58 
mg, 0.18 mmol) were subjected to the general conditions for 
16 h to afford the trans-alkene intermediate as a colorless oil 
(70 mg, 69%). trans-Alkene intermediate (76 mg, 0.13 mmol) 
was subjected to the general conditions to afford trans-ketone 
intermediate as a colorless oil (52 mg, 68%). trans-Ketone 
intermediate (47 mg, 0.082 mmol) was subjected to the 
general conditions to afford trans-10c as a pale orange solid (5 
mg, 10%). M.p.: 58 °C (decomp.); 
1
H NMR (400 MHz, DMSO-
d
6 ? ?ɷ 8.30 (1H, s), 8.20 (2H, br), 5.14 (1H, d, J = 18.0 Hz), 5.09 
(1H, d, J = 18.0 Hz), 4.68 (2H, app s), 3.96 (2H, app s), 3.72 (2H, 
app s), 3.56  ? 3.26 (peaks not fully resolved due to overlap 
with residual H2O), 3.27  ? 3.09 (3H, m), 2.90 (2H, dd, J = 17.5, 
6.0 Hz),  1.98  ? 1.88 (1H, m), 1.88  ? 1.76 (1H, m), 1.70  ? 1.53 
(1H, m), 1.54  ? 1.37 (1H, m); 13C NMR (100.6 MHz, DMSO-d6 ? ?ɷ 
200.6, 158.7, 149.2, 146.5, 133.8, 133.2, 132.8, 126.6, 123.3, 
66.9, 63.2, 56.2, 55.9, 54.5, 51.5, 43.0, 30.6, 20.2  ? one peak 
not resolved due to overlap with DMSO-d
6
; FTIR: vmax (neat) 
3011 (w), 2984 (w), 1677 (m), 1610 (m), 1278 (s), 1258 (s); 
HRMS calculated for C21H28
35
ClN4O4 (ES
+
)(+H
+
): 435.1794. 
Found: 435.1807. 
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